Follow The Filings

CRBP Corbus Pharmaceuticals Holdings

Health Care, filed as CORBUS PHARMACEUTICALS HLDGS (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.2%
  • $1M
  • 1 new

In 2026 Q2 Nathan Fischel opened a position in Corbus Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 0.2% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel New 0.19%

Who owns CRBP

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.19% New 0.19% 107,773 $1M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CRBP's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CRBP insider trades
  • $126K bought by 1 insider
  • $344K sold by 1 insider outside a trading plan
  • $381K sold by 6 insiders under 10b5-1 plans
  1. Yong Ben Director
    Planned sale
    $16K 2,000 shares at $7.84 18% of stake
    Traded Sep 14 Filed Sep 15
    ↗
  2. Nishant C Saxena Chief Business Officer
    Buy
    $25K 2,600 shares at $9.63 +3.5% to stake
    Traded Aug 11 Filed Aug 12
    ↗
  3. Yuval Cohen CEO
    Planned sale
    $171K 17,000 shares at $10.08 9.8% of stake
    Traded Aug 7 Filed Aug 10
    ↗
  4. Sean F. Moran CFO
    Planned sale
    $121K 12,000 shares at $10.08 12% of stake
    Traded Aug 7 Filed Aug 10
    ↗
  5. Winston Kung Director
    Planned sale
    $16K 2,026 shares at $7.91 14% of stake
    Traded Jun 10 Filed Jun 11
    ↗
  6. John Kenneth Jenkins Director
    Planned sale
    $38K 4,800 shares at $7.91 56% of stake
    Traded Jun 10 Filed Jun 11
    ↗
  7. Anne Altmeyer Director
    Planned sale
    $19K 2,412 shares at $7.91 24% of stake
    Traded Jun 10 Filed Jun 11
    ↗
  8. Nishant C Saxena Chief Business Officer
    Buy
    $101K 13,500 shares at $7.50 +22% to stake
    Traded Jun 2–3 Filed Jun 3
    ↗
  9. Cormorant Asset Management, LP 10% owner, +2 joint filers
    Sale
    $344K 30,029 shares at $11.46 1.3% of stake
    Traded Dec 11, 2025 Filed Dec 15, 2025
    ↗
  10. Yuval Cohen CEO
    Planned sale
    $471K 27,633 shares at $17.05 17% of stake
    Traded Oct 24–27 Filed Oct 27, 2025
    ↗
  11. Sean F. Moran CFO
    Planned sale
    $221K 12,981 shares at $17.02 15% of stake
    Traded Oct 24, 2025 Filed Oct 27, 2025
    ↗
  12. Anne Altmeyer Director
    Planned sale
    $22K 1,060 shares at $20.50 15% of stake
    Traded Oct 20, 2025 Filed Oct 21, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants and 6 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 1.01,5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07,7.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
DEFA14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.02,7.01,8.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
424B3 Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$44.6M -$40.21M -$78.54M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $23.55M $152.98M $166.95M
Total non-current assets * $4.73M $2.9M $1.24M
Total assets $28.27M $155.88M $168.2M
Total current liabilities $31.89M $11.82M $20.69M
Total non-current liabilities * $3.28M $1.63M $0M
Total equity -$6.9M $142.43M $147.5M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$36.1M -$41.79M -$64.49M
Cash from investing $35.64M -$121.31M -$1.64M
Cash from financing -$2.82M $166.58M $77.43M
Net change in cash -$3.28M $3.47M $11.29M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.